利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.024 秒)

    Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
    1.
    发明公开
    Triazole compouds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 有权
    Triazolfürdie Behandlung von auf die Modulation des Dopamin D3 Rezeptors ansprechende Krankheiten

    公开(公告)号：EP1484330A1

    公开(公告)日：2004-12-08

    申请号：EP04013358.9

    申请日：2004-06-07

    申请人： Abbott GmbH & Co. KG

    发明人： Haupt, Andreas ,  Grandel, Roland ,  Braje, Wilfried ,  Geneste, Hervé ,  Drescher, Karla ,  Starck, Dorothea ,  Teschendorf, Hans-Jürgen

    IPC分类号： C07D403/12 ,  A61K31/506 ,  A61P25/18

    CPC分类号： C07D403/12

    摘要： The invention relates to triazole compounds of the general formula I
    wherein
    R 1 is hydrogen or methyl, and
    R 2 is C 3 -C 4 alkyl or C 1 -C 2 fluoroalkyl,
    as well as the physiologically tolerated acid addition salts of these compounds.
    The invention also relates to a pharmaceutical composition that comprises at least one triazole compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists, said method comprising administering an effective amount of at least one triazole compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.

    摘要翻译： 本发明涉及通式I 的三唑化合物，其中R 1为氢或甲基，R 2为C 3 -C 4烷基或C 1 -C 2氟代烷基，以及生理学上可耐受的酸加成盐 这些化合物。 本发明还涉及包含至少一种式I的三唑化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D3的病症的方法 受体拮抗剂或多巴胺D3激动剂，所述方法包括向有需要的受试者施用有效量的至少一种式III的三唑化合物或生理学上耐受的酸加成盐。

    Tetrahydrobenzazepines and their use in the modulation of the dopamine D3 receptor
    4.
    发明公开
    Tetrahydrobenzazepines and their use in the modulation of the dopamine D3 receptor 审中-公开
    四氢苯并吖庚因和多巴因-D3-调节剂的调制

    公开(公告)号：EP2332543A1

    公开(公告)日：2011-06-15

    申请号：EP10193184.8

    申请日：2004-12-17

    申请人： Abbott GmbH & Co. KG

    发明人： Braje, Wilfried ,  Haupt, Andreas ,  Lubisch, Wilfried ,  Grandel, Roland ,  Drescher, Karla ,  Geneste, Hervé ,  Unger, Liliane ,  Sauer, Daryl

    IPC分类号： A61K31/55 ,  C07D223/16 ,  A61P25/00 ,  C07D409/12

    CPC分类号： C07D223/16 ,  A61K31/55 ,  C07D409/12

    摘要： The invention relates to tetrahydrobenzazepines of the general formula I

    in which the variables Ar, A, B, Y, R 1 and R 2 have the meanings indicated in claim 1, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides.
    The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to a compound according to the present invention for use in treating disorders that respond beneficially to dopamine D 3 receptor antagonists or dopamine D 3 agonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.

    摘要翻译： 本发明涉及通式I的四氢苯并吖庚因，其中变量Ar，A，B，Y，R 1和R 2具有权利要求1中所示的含义，以及这些化合物的N-氧化物，生理耐受酸 这些化合物的加成盐和N-氧化物的生理上耐受的酸加成盐。 本发明还涉及药物组合物，其包含至少一种式I的四氢苯并氮杂化合物，I的物理耐受的酸加成盐，式I化合物的N-氧化物和/或其物理上耐受的酸加成盐 I的N-氧化物，并且进一步用于本发明化合物，用于治疗有利于多巴胺D 3受体拮抗剂或多巴胺D 3激动剂的病症。 根据本发明的化合物优选可用于治疗中枢神经系统疾病如精神分裂症和抑郁症以及治疗肾功能障碍。

    Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
    7.
    发明公开
    Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 审中-公开
    为DopaminD3受体响应的疾病的调制的治疗杂环化合物

    公开(公告)号：EP2311803A1

    公开(公告)日：2011-04-20

    申请号：EP10183342.4

    申请日：2005-10-14

    申请人： Abbott GmbH & Co. KG

    发明人： Drescher, Karla ,  Haupt, Andreas ,  Unger, Liliane ,  Turner, Sean C. ,  Braje, Wilfried ,  Grandel, Roland ,  Henry, Christophe ,  Backfisch, Gisela ,  Beyerbach, Armin ,  Lubisch, Wilfried

    IPC分类号： C07D207/09 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D401/04 ,  C07D403/04 ,  C07D413/12 ,  C07D205/04 ,  C07D413/10 ,  C07D413/14 ,  C07D211/28 ,  A61K31/397 ,  A61K31/40 ,  A61K31/445 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24

    CPC分类号： C07D413/14 ,  C07D205/04 ,  C07D207/09 ,  C07D211/28 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/12 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12

    摘要： The invention relates to compounds of the formula (I)

    wherein
    n
    is 0, 1 or 2;
    G
    is CH 2 or CHR 3 ;
    R 1
    is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl;
    R 2 R 3 and R 4
    are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;
    A
    is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ;
    E
    is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl;
    Ar
    is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description;

    and physiologically tolerated acid addition salts thereof.
    The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

    摘要翻译： 本发明涉及式（I）的worin化合物n是0,1或2; G为CH 2或CHR 3; R 1为H，C 1 -C 6烷基，C 1 -C 6烷基被C 3 -C 6环烷基取代，C 1 -C 6羟基烷基，氟化的C 1 -C 6烷基，C 3 - C 6环烷基，氟化的C 3 -C 6环烷基，C 3 -C 6链烯基，氟化的C 3 -C 6链烯基，甲酰基，乙酰基或丙酰基; R 2 R 3和R 4，彼此独立地为H，甲基，氟甲基，二氟甲基，或三氟甲基的; A为亚苯基，吡啶基，嘧啶基，吡嗪基，哒嗪或噻吩，其可被选自卤素，甲基，甲氧基和CF 3中选择的一种或多种取代基所substituiertem; E为NR 5或CH 2，worin R 5为H或C 1 -C 3烷基; Ar是环状基团选自苯基中选择，5-或6-元杂芳基基团，其包括作为环成员1，2或选自N，O和S的和稠合的饱和或不饱和5的苯基环中的杂原子3 - 或6-元碳环或杂环，其中所述杂环包含作为环成员1，选自N，O和S和/或1,2或3个含杂原子基团中选择2或3的杂原子各自独立地选自NR 8中选择， 其中R 8是H，C 1 -C 4烷基，氟代C 1 -C 4烷基，C 1 -C 4烷基羰基或氟化的C 1 -C 4烷基羰基，并且其中该环状基团Ar可以携带1， 2个或3个取代基R a，worin变量R a具有在权利要求和说明书中给出的含义; 和生理上容许的其酸加成盐。 因此，本发明涉及使用式I化合物或用于制备用于医学病症易于与多巴胺D 3受体配体治疗的治疗药物组合物的药学上可接受的盐。

    Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
    8.
    发明公开
    Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor 审中-公开
    杂环化合物，以响应治疗与受体Dopamind3疾病的调制

    公开(公告)号：EP2311802A1

    公开(公告)日：2011-04-20

    申请号：EP10183328.3

    申请日：2005-10-14

    申请人： Abbott GmbH & Co. KG

    发明人： Drescher, Karla ,  Haupt, Andreas ,  Unger, Liliane ,  Turner, Sean C. ,  Braje, Wilfried ,  Grandel, Roland ,  Henry, Christophe ,  Backfisch, Gisela ,  Beyerbach, Armin ,  Lubisch, Wilfried

    IPC分类号： C07D207/09 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D401/04 ,  C07D403/04 ,  C07D413/12 ,  C07D205/04 ,  C07D413/10 ,  C07D413/14 ,  C07D211/28 ,  A61K31/397 ,  A61K31/40 ,  A61K31/445 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24

    CPC分类号： C07D413/14 ,  C07D205/04 ,  C07D207/09 ,  C07D211/28 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/12 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12

    摘要： The invention relates to compounds of the formula (I)

    wherein
    n is 0,1 or 2;
    G is CH 2 or CHR 3 ;
    R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl;
    R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl;
    A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ;
    E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl;
    Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 3 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description;

    and physiologically tolerated acid addition salts thereof.
    The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

    摘要翻译： 本发明涉及式（I）worin n为0.1或2的化合物; G为CH 2或CHR 3; R 1为H，C 1 -C 6烷基，C 1 -C 6烷基被C 3 -C 6环烷基取代，C 1 -C 6羟基烷基，氟化的C 1 -C 6烷基，C 3 - C 6环烷基，氟化的C 3 -C 6环烷基，C 3 -C 6链烯基，氟化的C 3 -C 6链烯基，甲酰基，乙酰基或丙酰基; R 2，R 3和R 4，彼此独立地为H，甲基，氟甲基，二氟甲基，或三氟甲基的; A为亚苯基，吡啶基，嘧啶基，吡嗪基，哒嗪或噻吩，其可被选自卤素，甲基，甲氧基和CF 3中选择的一种或多种取代基所substituiertem; E为NR 5或CH 2，worin R 5为H或C 1 -C 3烷基; Ar是环状基团选自苯基中选择，5-或6-元杂芳基基团，其包括作为环成员1，2或选自N，O和S的和稠合的饱和或不饱和5的苯基环中的杂原子3 - 或6-元碳环或杂环，其中所述杂环包含作为环成员1，选自N，O和S和/或1,2或3个含杂原子基团中选择2或3的杂原子各自独立地选自NR 8中选择， 当R 3为H，C 1 -C 4烷基，氟代C 1 -C 4烷基，C 1 -C 4烷基羰基或氟化的C 1 -C 4烷基羰基，并且其中该环状基团Ar可以携带1， 2个或3个取代基R a，worin变量R a具有在权利要求和说明书中给出的含义; 和生理上容许的其酸加成盐。 因此，本发明涉及使用式I化合物或用于制备用于医学病症易于与多巴胺D 3受体配体治疗的治疗药物组合物的药学上可接受的盐。